These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 14, 2020
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...
Aug 6, 2020Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Sierra Oncology, Inc....
Aug 6, 2020
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1...
Jul 28, 2020
- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company - VANCOUVER, British Columbia,...
Jun 12, 2020
- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - -...